Findings from the MARIPOSA trial support the FDA approval of frontline amivantamab/lazertinib in advanced or metastatic EGFR-mutant NSCLC.
Approval Alert | Amivantamab/Lazertinib in Advanced EGFR+ NSCLC
Advertisement
Advertisement
Trending on CancerNetwork
1
Atezolizumab Combo Elicits No Significant Benefit in Ovarian Cancer
2
How Will Gastrointestinal Cancer Standards of Care Change? An ESMO Recap
3
Glofitamab/Polatuzumab Vedotin Exhibits Response Durability in R/R LBCL
4
Forming CUTNETs: A Joint Venture Between Surgery and Oncology in NETs
5
